Author Archives: pancreatica
FDA Approval: Nab-paclitaxel in Combination with Gemcitabine for Pancreatic Cancer
On September 6th the U.S Food and Drug Administration (FDA) – per its commendable fast track expedited review program for “orphan” diseases (which now includes pancreatic cancer) has approved nab-paclitaxel (trade name: Abraxane) for use in in combination with gemcitabine for metastatic pancreatic cancer (ductal adenocarcinoma of the pancreas). The previous drug agent officially approved […]
Chemotherapy Regimen for NET: Platinum Agent Plus Topoisomerase Inhibitor
The exploration of chemotherapy for advanced pancreatic neuroendocrine tumors has been somewhat sparse, but has increased pace during the past few years. Certain of these regimens have met with some success, increasing the armamentarium of clinicians. Beijing, China researchers led by Shen from the Peking University School of Oncology have published an article in the […]
Heavy-duty Multimodal Therapy with RFA for Locally Advanced Pancreatic Cancer
In some ways, both early stage and late stage pancreatic cancer (under current thinking paradigms) may be easier stages in which to offer standard care: early receives surgery (without or without neoadjuvant or adjuvant augmentation), and late stage is typically chemotherapy in one combination or another – at least initially involving either gemcitabine or 5-FU. […]
Hepatitis as a Risk Factor for Pancreatic Cancer
A number of odd or non-intuitive relationships between apparently unrelated variables and pancreatic cancer (ductal adenocarcinoma of the pancreas) are beginning to emerge – including ABO blood status, and now some forms of hepatitis. In the World Journal of Gastroenterology from July 14, 2013, Chen and colleagues from the Southern Medical University, in Guangzhou, China […]
Cryotherapy plus Biologic Therapy for Advanced Cancer of the Pancreas
It is the impression of this author that in the past decade or so the quantity and quality of published medical research coming from China has increased rather remarkably. This has included challenges to “standard” established practice – with innovative ideas particularly on the treatment of pancreatic cancer (ductal adenocarcinoma of the pancreas). Now comes […]